// Focus areas

Three areas,
one biology.

The science underneath is shared. A protein engineered for a diagnostic assay and one engineered for a vaccine candidate are solved with the same tools — which is why we work across all three rather than picking one.

Areas
Three, worked in parallel
Shared
One protein design platform
Applied to
Binders, antigens, constructs
Open to
Ventures, labs, institutions

The three focus areas

// One platform

The same tools, three outputs.

Working across all three is a technical decision before it is a commercial one.

A binder for an immunoassay and a binder for a therapeutic are optimised against different constraints, but they are designed, ranked and tested with the same machinery: structure prediction, sequence models, in-silico screening, and a laboratory loop that feeds results back.

That shared machinery is why a result in one area tends to move the others. An expression strategy worked out for a diagnostic antigen is often the strategy that rescues a vaccine immunogen. A stability fix found for a biologic is the same fix that makes a reagent survive shipping to a clinical laboratory in a hot climate.

What differs between them

  • Diagnostics optimise for specificity, signal and cost at volume.
  • Drug development optimises for target engagement and a defensible data package.
  • Therapeutics optimise for stability, expression and manufacturability.
  • Vaccine development optimises for immunogen presentation and durability.

What stays the same

The protein has to be designed, made, measured and improved. That loop is where we work, and it is the part we can shorten.

// Related areas

And what
sits around it.

The three focus areas do not stand alone. These are the adjacent capabilities a biotechnology programme draws on.

  • Protein engineering
  • Bioinformatics
  • Computational biology
  • Assay & reagent supply
  • Laboratory instrumentation
  • Regulatory affairs
  • Market access
  • Authorised distribution
Related areas and regional reach ↗